Table 5.
Pathological response in patients of the study cohort with different PD-L1 TPS.
Study cohort | Pathological response | ||
---|---|---|---|
PD-L1 TPS (NA 3) | n | MPR | pCR |
⩾50% | 27 | 20 (74%) | 16 (59%) |
1–49% | 25 | 16 (64%) | 12 (48%) |
0% | 4 | 2 (50%) | 1 (25%) |
MPR, major pathological response; pCR, complete pathological response, PD-L1, programmed-death ligand 1; TPS, tumour-proportion score.